Dr Sun 講的挺對，機體狀態恢複一下，做免疫治療比較好。您的親屬，經過化療 自體骨髓移植，又有病情發展，估計可能沒達到或短暫緩解。很可能是難治一類的淋巴瘤。淋巴瘤基本有兩大類， 何傑金（HL）和非何傑金（NHL）淋巴瘤，前者預後較好，後者中也有不少類型，其中一些類型比較難治，預後不好。不知道您親屬什麽類型。PD-1或類似PD-1的抗體藥物，在淋巴瘤裏已開始臨床試驗。 其中Nivolumab 和 pembrolizumab效果還不太明確。另一種Pidilizumab療效看起來挺好。如果經濟條件允許您親屬可以試試，如 Dr.Sun講的，機體狀態得回複，下邊的Pidilizumab治療 也是在減少腫瘤負荷量前提下做的。
報告說：A phase II single-arm international study of pidilizumab in relapsed or refractory DLBCL or primary mediastinal B-cell lymphoma （彌漫大B細胞淋巴瘤 和 原發性縱隔B細胞淋巴瘤，這兩類都不太好治療） after autologous stem cell transplant was performed with the rationale that PD-1 blockade post-transplant would be effective due to low-volume disease and the potential for immune remodeling. The study included 66 patients. In the 35 patients with measurable disease, the overall response rate was 51%, with 34% achieving complete response and 37% achieving stable disease. Correlative studies demonstrated an increase in PD-L1-bearing circulating lymphocytes, apparent 24 h after pidilizumab treatment, and sustained until almost 16 weeks. Subsequently, the drug was evaluated in conjunction with rituximab in a phase II single-arm open label study of 29 eligible patients with relapsed, refractory follicular lymphoma. There were no highgrade treatment-related adverse events, and the overall response rate was 66%, with an impressive 52% complete response rate.
